SHANGHAI, July 19, 2018 /PRNewswire/ -- Shanghai Green Valley Pharmaceutical Co., Ltd. (Green Valley) today announced
This randomized, double-blinded and placebo-controlled clinical trial in China aimed to evaluate safety and efficacy of GV-971, a multi-targeting oligosaccharide drug, on study participants with mild-to-moderate Alzheimer's disease (MMSE score ranged from 11 to 26). Subjects took 450mg GV-971 orally twice each day for 36 weeks. The primary endpoint showed the improved change of the Alzheimer's Disease Assessment Scale-cognitive (ADAS-cog) score after the 36 week GV-971 treatment compared to the placebo control. GV-971 showed a similar profile to that of the placebo, no amyloid-related imaging abnormalities (ARIA) were observed.
Alzheimer's disease is a chronic neurodegenerative disorder characterized by a progressive loss of cognitive function. According to Alzheimer's Disease International, there are approximately 48 million patients world-wide with Alzheimer's disease, and this number is expected to reach 130 million by 2050 due to a rapid growth of the aging population.
Green Valley plans to submit the marketing authorization application of GV-971 for treatment of mild-to-moderate Alzheimer's disease to the China National Drug Administration later this year.
View original content:http://www.prnewswire.com/news-releases/innovative-alzheimers-treatment-from-china-concludes-phase-3-clinical-trials-300683455.html
SOURCE Shanghai Green Valley Pharmaceutical Co., Ltd
Subscribe to our Free Newsletters!
Graviola''s health benefits range from curing headaches to fighting cancer. Read on to know more ...
Gene therapy is a specialized procedure where genetic material is introduced into the cells of a ...
The orange-like citrus fruit, Kumquat, is a complete health booster if included regularly in your ...View All